This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 6
  • /
  • Tarsus Pharmaceuticals Inc. announces positive res...

Tarsus Pharmaceuticals Inc. announces positive results of Saturn-1 pivotal trial of TP 03 for the treatment of Demodex blepharitis.

Read time: 3 mins
Published:27th Jun 2021
Tarsus Pharmaceuticals, Inc. announced that all pre-specified primary and secondary endpoints were met for its pivotal Phase IIb/III Saturn-1 trial evaluating the company’s novel investigational therapeutic, TP 03 (lotilaner ophthalmic solution, 0.25%), in patients with Demodex blepharitis.

Results demonstrated a statistically significant complete collarette cure at day 43 in patients with Demodex blepharitis treated with TP 03 compared to vehicle (p<0.0001; primary endpoint). the saturn-1 trial also met the secondary endpoints of mite eradication at day 43 (p><0.0001) and composite cure based on complete collarette and erythema cures at day 43 (p><0.0001). in addition, significant, clinically meaningful improvements were observed within two weeks across multiple endpoints. tp 03 was well tolerated with a safety profile similar to vehicle, and there were no treatment-related discontinuations.></0.0001).></0.0001)></0.0001;>

“Millions of people are living with Demodex blepharitis, and we know from recent research that these patients are suffering daily. With no FDA-approved therapies, both patients and eye care professionals need a solution to eradicate the mites that cause the disease,” said Bobak Azamian, M.D., Ph.D., President and Chief Executive Officer of Tarsus. “We believe the results from our Saturn-1 trial mark an important moment in Demodex blepharitis research, showing the potential of TP 03 to target the underlying cause of this disease and potentially become the standard of care for patients and clinicians. We expect to provide topline results for our second pivotal trial for TP 03, Saturn-2, in Q1 of 2022. If Saturn-2 trial data is positive, similar to the positive Saturn-1 results, we expect both Saturn-1 and Saturn-2 trials to support our submission of a New Drug Application (NDA) for TP 03 for the treatment of Demodex blepharitis in 2022.”

Demodex blepharitis is a highly prevalent ocular disease, affecting as many as 25 million Americans, that can have a significant clinical burden and negatively impact patients’ daily lives. The disease is caused by an infestation of Demodex mites, the most common ectoparasite found on humans, that live on the skin of the face and eyelids. Demodex blepharitis is characterized by inflammation of the eyelid margin, redness and ocular irritation. TP 03 has the potential to be the first FDA-approved therapeutic for Demodex blepharitis and targets the underlying cause of disease – Demodex mite infestation. The Saturn-1 trial is the first large-scale trial to show positive, clinically meaningful results for a therapeutic specifically designed to treat Demodex blepharitis.

Saturn-1 Phase IIb/III Results demonstrated 81% of patients achieved a significant, clinically meaningful collarette cure defined by a collarette grade of zero (0) or one (1) at day 43 compared to 23% of those on vehicle (p<0.0001). additionally, a significant, clinically meaningful collarette cure was seen in 23% of patients on tp-03 compared to 11% on vehicle as early as day 8 (p="0.0003)." saturn-1 data also showed that 43% of patients on tp-03 achieved the primary endpoint of complete collarette cure (grade 0) at day 43, defined as zero to two (0-2) collarettes per lid compared to 7% on vehicle (p><0.0001). collarettes, a pathognomonic sign of demodex infestation, are composed of partially digested epithelial cells, mite waste products and eggs and are most easily observed at the base of the upper eyelashes when the patient looks down during a standard eye examination. the secondary endpoint of complete mite eradication achieved statistically significant results by day 15, and 68% of patients on tp 03 achieved mite eradication compared to 18% on vehicle (p><0.0001) at day 43. mite eradication is defined as a mite density of zero (0) mites per lash.></0.0001)></0.0001).></0.0001).>

For composite cure, 68% of patients experienced a significant, clinically meaningful cure of both a grade zero (0) or one (1) collarette and erythema score at day 43 compared to 20% on vehicle (p<0.0001), with significant improvements seen as early as day 8. additionally, 13.4% of patients on tp 03 achieved a complete composite cure, which was another secondary endpoint, based on a composite of collarette cure and erythema cure compared to 1.0% on vehicle (p><0.0001) at day 43. composite cure is defined as the presence of zero to two (0-2) collarettes on the upper eyelid and the absence of erythema (redness). results for complete erythema cure (19% of patients on tp-03 compared to 7% of patients on vehicle, p><0.0001) and one (1) grade or more erythema improvement (45% of patients on tp-03 compared to 28% of patients on vehicle, p="0.0002)" were also statistically significant.></0.0001)></0.0001)></0.0001),>

Trial Safety Data : TP 03 is a well-characterized anti-parasitic agent that paralyzes and eradicates Demodex mites by selectively inhibiting parasite-specific GABA-Cl channels. Saturn-1 trial results demonstrated that TP 03 was well tolerated with a safety profile similar to the vehicle group. Additionally, most TP 03 patients (92%) reported that the drop comfort was neutral to very comfortable. There were no serious treatment-related adverse events nor any treatment-related adverse events leading to treatment discontinuation. All treatment-related ocular adverse events in the TP 03 group were mild with the most common being instillation site pain/burning/stinging (11.8%, n=25). Other adverse events occurring at a rate of ?1% in the TP03 group included instillation site pruritis, reduced visual acuity, eye pain and eye discharge, each representing 1.4% (n=3) of patients.

Condition: Demodex Blepharitis
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.